Clinical Trials Logo

Clinical Trial Summary

Cannabis users who experienced a psychosis are particularly vulnerable to cannabis-related harms, which can include worse psychotic symptoms and more hospitalizations. Unfortunately, few psychosocial interventions exist that aim to decrease these harms. Instead, most focus on ceasing cannabis use which is rarely appealing to cannabis users. Furthermore, face-to-face psychotherapy often remains inaccessible to people with psychosis mostly due to lack of trained clinicians. Alternatives such as e-interventions have the potential to increase access to treatment and decrease clinicians' workload. Among cannabis harm reduction approaches are the protective behavioural strategies. These strategies do not encourage nor discourage cannabis use. Instead, they recommend behaviours for safer cannabis use. For example, these strategies include: 1) avoid driving a car under the influence of cannabis, 2) avoid mixing cannabis with other drugs and 3) purchase cannabis only from a trusted source. In the present pan-Canadian study, we will test the first e-intervention called CHAMPS (Cannabis Harm-reducing App for Managing Practices Safely) for cannabis harm reduction adapted for young adult cannabis users who experienced a psychosis. CHAMPS is a smartphone application that includes 17 strategies for safer cannabis use, a personalized consumption goal and a consumption journal. The goals of this study are 1) to confirm whether CHAMPS is acceptable to participants and 2) to test whether it works, notably by positively impacting participants' health and cannabis consumption habits.


Clinical Trial Description

This multicentric, two-arm, open-labelled, pilot randomized controlled trial involves 100 young cannabis users who experienced a psychosis and are followed in an early intervention service (EIS) in Canada. Participants will be randomized in a 1:1 ratio to one of two interventions: - CHAMPS and EIS - EIS alone The smartphone application CHAMPS contains six modules (each lasting 15-20 min, weeks 1 to 6) and a booster session (20 min, week 10) based on motivational interviewing and harm reduction approaches. EIS consists of standard of care and psychoeducation material on cannabis use offered in first episode psychosis clinics and administered through in-person visits and/or phone or video calls. All participants will be assessed for a follow-up at weeks 6, 12 and 18. Data on mental health, substance use, cannabis dependence severity, cannabis-related problems, quality of life and health care service utilization will be obtained through questionnaires and medical charts. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04968275
Study type Interventional
Source Centre hospitalier de l'Université de Montréal (CHUM)
Contact
Status Completed
Phase N/A
Start date August 23, 2021
Completion date October 24, 2023

See also
  Status Clinical Trial Phase
Completed NCT02306551 - Well Being And Resilience: Mechanisms of Transmission of Health and Risk
Active, not recruiting NCT00627029 - Evaluation of Programs of Coordinated Care and Disease Management N/A
Terminated NCT00049738 - Screening for Childhood-Onset Psychotic Disorders N/A
Withdrawn NCT01724372 - The Role of Antidepressants or Antipsychotics in Preventing Psychosis N/A
Completed NCT00716755 - Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia. N/A
Completed NCT00498550 - Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Phase 4
Terminated NCT04140773 - The Effect of D-serine as add-on Therapy in Recent-onset Psychosis N/A
Completed NCT01473550 - Mental Health Engagement Network (MHEN) N/A
Completed NCT01207219 - Yoga and Aerobic Exercise in Psychosis N/A
Completed NCT00397033 - Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder. Phase 3
Recruiting NCT04945278 - Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological Vulnerability N/A
Completed NCT03955250 - Mobile After-Care Support App: Pilot RCT N/A
Completed NCT00287352 - Study of Amantadine for Weight Stabilization During Olanzapine Treatment Phase 1
Completed NCT00005658 - Glycine to Treat Psychotic Disorders in Children Phase 2
Terminated NCT00169026 - Alcoholism and Schizophrenia: Effects of Clozapine Phase 4
Completed NCT00001482 - New Drugs in the Treatment of Mood Disorders Phase 2
Terminated NCT03671005 - Mindfulness-based Group Therapy for Inpatients With Schizophrenia Spectrum Disorders N/A
Completed NCT00156715 - Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder Phase 4
Completed NCT00095524 - Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder Phase 3
Completed NCT03667729 - The Effects of Progressive Muscle Relaxation Therapy in Patients With Schizophrenia N/A